Presepsin在新生儿败血症早期诊断中的研究进展  

Research progress of presepsin in the early diagnosis of neonatal sepsis

作　　者：张华清 胡晓艳[1] Zhang Huaqing;Hu Xiaoyan(Department of Pediatric,Peking University Shenzhen Hospital,shenzhen China)

机构地区：[1]北京大学深圳医院儿科,深圳518036

出　　处：《中国综合临床》2024年第3期237-240,共4页Clinical Medicine of China

摘　　要：新生儿败血症是新生儿期的严重感染性疾病,可引起感染性休克和多器官功能衰竭等严重并发症,危及患儿生命,早期诊断是改善预后的关键环节。因新生儿败血症临床表现往往不典型,难以早期觉察,因此临床上急需可靠的感染标志物帮助早期诊断。目前应用于临床的诊断指标均存在一定的局限性。近年来发现一种新型标记物Presepsin(可溶性CD14分子亚型,sCD14-TS),有望成为新生儿败血症早期诊断的理想标志物。Neonatal sepsis is a serious infectious disease in the neonatal period,which can cause severe complications such as septic shock and multiple organ failure,and endangering children's lives.Early diagnosis is the key to improve the prognosis.Because the clinical manifestations of neonatal sepsis are often atypical and difficult to be detected early,reliable infection markers are urgently needed to help the early diagnosis.Recently,a novel marker Presepsin(soluble CD14 subtype,sCD14-TS)has been found,which is expected to be an ideal marker for the early diagnosis of neonatal sepsis.

关 键 词：新生儿败血症 可溶性CD14分子亚型 降钙素原 C反应蛋白 

分 类 号：R722.131[医药卫生—儿科]